Wires

Roche drug fails in early-onset Alzheimer's disease study

ZURICH, Feb 10 (Reuters) - Roche said its experimental Alzheimer's disease drug gantenerumab did not show a significant slowing of the rate of cognitive decline in people with a rare inherited form of the devastating brain wasting disease.

Roche said the study's failure will not impact two ongoing late-stage studies of gantenerumab in people with common form of Alzheimer's disease that is not directly caused by gene mutations. (Reporting by John Miller; editing by Thomas Seythal)